Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline ProgressBusiness Wire • 05/08/25
Takeda Pharmaceutical Co. (TAK) Upgraded to Strong Buy: Here's What You Should KnowZacks Investment Research • 05/07/25
BioLife Plasma Services Introduces the New Fresenius Kabi Adaptive Nomogram Across its U.S. Network of Plasma Donation CentersBusiness Wire • 05/05/25
Are You Looking for a Top Momentum Pick? Why Takeda Pharmaceutical Co. (TAK) is a Great ChoiceZacks Investment Research • 04/30/25
Takeda Awards $13.8 Million to U.S. Nonprofit Partners to Promote Healthy Eating and Expand STEM EducationBusiness Wire • 04/30/25
Takeda & Protagonist: Rusfertide Clinical Success Bolsters Investment ReturnsSeeking Alpha • 04/01/25
Is Takeda Pharmaceutical Co. (TAK) a Great Value Stock Right Now?Zacks Investment Research • 03/19/25
Takeda: Buy Into Future Drug Pipeline Potential, Despite Recent Profit HeadwindsSeeking Alpha • 03/13/25
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia VeraBusiness Wire • 03/03/25
The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)PRNewsWire • 02/24/25
Strong Q3, Improved Guidance Are Signs Takeda Pharmaceutical May Be UndervaluedSeeking Alpha • 01/31/25
Suffolk Celebrates Topping off for a Game-Changing New Takeda Facility in Kendall Square Where Science, Art and Community Will ConvergeBusiness Wire • 01/30/25
Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin GrowthBusiness Wire • 01/30/25